Necuparanib
- Generic Name
- Necuparanib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 1415139-34-2
- Unique Ingredient Identifier
- ULS0NT2D68
- Background
Necuparanib is under investigation in clinical trial NCT01621243 (M402 in Combination With Nab-paclitaxel and Gemcitabine in Pancreatic Cancer).
- Associated Conditions
- -
- Associated Therapies
- -
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2012-06-18
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Momenta Pharmaceuticals, Inc.
- Target Recruit Count
- 128
- Registration Number
- NCT01621243
- Locations
- 🇺🇸
Metro-Minnesota Community Clinical Oncology Program, Saint Louis Park, Minnesota, United States
🇺🇸Illinois Cancer Specialists, Arlington Heights, Illinois, United States
🇺🇸University of New Mexico Cancer Center, Albuquerque, New Mexico, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath